Henry Ford Hospital is embarking on an expanded major clinical trial involving the use of gene therapy in combination with radiation therapy, to determine if the combined treatment is more effective than radiation therapy alone for patients with intermediate risk prostate cancer.
The clinical trial is part of a $9 million grant from the National Cancer Institute (NCI) awarded to Henry Ford to study the effectiveness of gene therapy to treat prostate cancer.
"As part of this research grant we have had encouraging results involving two smaller clinical studies," says Svend Freytag, Ph.D., division head of Research, Radiation Oncology, Henry Ford Hospital.
Dr. Freytag, along with Benjamin Movsas, M.D., chair of Radiation Oncology and Hans Stricker, M.D., vice chair of Urology at Henry Ford Hospital are the study's key researchers.
MedicalNewsToday
Thursday, February 7, 2008
Research On Gene And Radiation Therapy For Prostate Cancer Expanded By Henry Ford Hospital
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment